Selected article for: "enzyme interaction and viral enzyme interaction"
Author: VanPatten, Sonya; He, Mingzhu; Altiti, Ahmad; F Cheng, Kai; Ghanem, Mustafa H; Al-Abed, Yousef
Title: Evidence supporting the use of peptides and peptidomimetics as potential SARS-CoV-2 (COVID-19) therapeutics
  • Cord-id: q263ggeo
  • Document date: 2020_7_16
    • ID: q263ggeo
    Snippet: During a disease outbreak/pandemic situation such as COVID-19, researchers are in a prime position to identify and develop peptide-based therapies, which could be more rapidly and cost-effectively advanced into a clinical setting. One drawback of natural peptide drugs, however, is their proteolytic instability; peptidomimetics can help to overcome this caveat. In this review, we summarize peptide and peptide-based therapeutics that target one main entry pathway of severe acute respiratory syndro
    Document: During a disease outbreak/pandemic situation such as COVID-19, researchers are in a prime position to identify and develop peptide-based therapies, which could be more rapidly and cost-effectively advanced into a clinical setting. One drawback of natural peptide drugs, however, is their proteolytic instability; peptidomimetics can help to overcome this caveat. In this review, we summarize peptide and peptide-based therapeutics that target one main entry pathway of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which involves the host angiotensin-converting enzyme-2 (ACE2) receptor and viral spike (S) protein interaction. Furthermore, we discuss the advantages of peptidomimetics and other potential targets that have been studied using peptide-based therapeutics for COVID-19.

    Search related documents:
    Co phrase search for related documents
    • active disease and low activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • active disease and low bioavailability: 1
    • active disease and lung alveolar: 1, 2
    • activity relationship and additional study: 1, 2
    • activity relationship and adhesion molecule: 1
    • activity relationship and low activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • activity relationship and low bioavailability: 1, 2, 3
    • activity relationship and low toxicity: 1, 2, 3
    • activity relationship and lung alveolar: 1
    • adhesion molecule and lung alveolar: 1, 2, 3
    • low toxicity and lung alveolar: 1